14 March 2018
The Nomination Committee of Immunicum AB (publ) proposes Michael Oredsson as new Chairman of the Board
The Nomination Committee of Immunicum (publ; IMMU.ST) has informed the Company that they will propose Michael Oredsson as new Chairman of the Board at the upcoming Annual General Meeting. Immunicum’s current Chairman of the Board, Agneta Edberg, has announced that she will not stand for re-election.
“The Nomination Committee is convinced that Michael’s broad and successful business background, combined with his specific knowledge of the competitive landscape of immuno-oncology, are important assets for the Company. Michael also has experience in initiating and managing collaborations with industrial partners, which is an element that will be of increasing value to have on the board,” said Chairman of the Nomination Committee, Martin Lindström.
“Immunicum has built a strong foundation and is well positioned for success as it moves into advanced clinical development for ilixadencel. This corporate evolution requires new expertise on the board,” continued Lindström.
Michael Oredsson holds an MSc in International Business Administration and was until the end of 2017 CEO of publically-listed Bioinvent. Prior to that, Michael was CEO of Probi (2007-2013), Biosignal in Australia (2002-2007) and Nutripharma in Norway (1999-2001). During the eighties and nineties, he worked in senior positions in companies such as Pharmacia, M & M/Mars and Nestlé. Michael is currently Chairman of Ectin AB and a board member of PULS AB. Former board experience includes LIDDS AB (ordf), SP, EBCRC and Biosignal in Australia.
The information is such information that Immunicum is obliged to make public pursuant to EU Market Abuse Regulation. The information was released for public disclosure through the contact persons detailed below on 14 March 2018 at 13:00 pm CET.
For more information, please contact:
Martin Lindström, Chairman of the Nomination Committee
Telephone: +46 (0) 70 368 6515
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 76 243 6810
About Immunicum AB (publ)
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com